Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Richard Belanger who wrote (30277)	1/14/2000 12:53:00 PM
From: Henry Niman	Respond to of 32384

I think that only shares held longer than 10 years should be allowed to vote :-).

To: Richard Belanger who wrote (30277)	1/14/2000 12:56:00 PM
From: Henry Niman	Respond to of 32384

Actually, It should be shares held longer than 12 years :-).

To: Richard Belanger who wrote (30277)	1/15/2000 8:50:00 PM
From: Henry Niman	Respond to of 32384

From San Diego Union on LGND (on Wednesday): "With $48 million in cash at the end of the third quarter and a long list of partnerships with bigger companies, Ligand is not in danger. Indeed, some analysts think its large portfolio of projects increases the chance of eventual success. "It's really positioned to become one of the next top-tier names," Chase H&Q analyst Richard van den Broek said. Robinson said the outlook is bright. He said Ligand should make money this year, and he said the company has stepped up its sales force to 40 people, which should boost sales of the cancer drugs Ontak and the recently approved Targretin. With three approved drugs -- including Panretin for AIDS lesions -- Ligand is far ahead of most other biotechs, which have no products on the market. But sales of Ontak and Panretin were minimal in their first year, though Robinson said Ontak is now "beginning to hit its rhythm in the marketplace." Aside from selling Ontak and Targretin more aggressively for cutaneous t-cell lymphoma, Robinson said the company will continue studies of both in other cancers -- which could greatly expand the potential market if successful. The company is looking at Ontak in non-Hodgkin's lymphoma and at Targretin in breast cancer and psoriasis.